Zacks.com on MSN5h
What Awaits These 4 Biotech Stocks That More Than Doubled in 2024The drug and biotech sector had a turbulent year in 2024, starting strong but losing momentum in the second half. This ...
The Food and Drug Administration (FDA) has approved Ryoncil ® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft vs host disease (SR-aGvHD) in pediatric patients 2 months of age ...
If you thought crypto investors need to have strong stomachs, spare a thought for the investors who try their luck in the ...
Regenerative medicine company Mesoblast Ltd. received an early Christmas present from the FDA for approval of its allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy, Ryoncil ...
Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, announced the Food and Drug Administration (FDA) approved Ryoncil (remestemcel-L) as the first mesenchymal ...
Email Alerts for: Current price: $2.63 Market cap: $3.93bn Current price: $3.01 Current price: $2.31 Current price: $3.69 ...
GEN presents data compiled by Morningstar's Morningstar Direct asset management platform for StockWatch of the top five ...
The U.S. Food and Drug Administration approved Ryoncil (remestemcel-L-rknd), an allogeneic (donor) bone marrow-derived ...
Meanwhile, synthetic gel aids in recovery after spinal surgery; Pittsburgh researchers create helper robots for people with ALS; a study finds nerve stimulation is effective against ...
With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help tech journalists and consumers stay on top of the week's most newsworthy ...
This week’s Bulls N’ Bears Runner of the Week is… icetana. The video analytic solution provider inked a 3-year Malaysian ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback